Log in

NYSE:BCDA - Biocardia Stock Price, Forecast & News

$3.67
+0.02 (+0.55 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$3.50
Now: $3.67
$3.67
50-Day Range
$3.65
MA: $4.64
$5.69
52-Week Range
$3.15
Now: $3.67
$17.50
Volume1,085 shs
Average Volume31,846 shs
Market Capitalization$25.05 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone650-226-0120

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees27
Market Cap$25.05 million
Next Earnings Date4/7/2020 (Estimated)
OptionableNot Optionable

Receive BCDA News and Ratings via Email

Sign-up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.


Biocardia (NYSE:BCDA) Frequently Asked Questions

What is Biocardia's stock symbol?

Biocardia trades on the New York Stock Exchange (NYSE) under the ticker symbol "BCDA."

When is Biocardia's next earnings date?

Biocardia is scheduled to release their next quarterly earnings announcement on Tuesday, April 7th 2020. View Earnings Estimates for Biocardia.

What is the consensus analysts' recommendation for Biocardia?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocardia in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biocardia.

Has Biocardia been receiving favorable news coverage?

News headlines about BCDA stock have been trending very negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Biocardia earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for Biocardia.

Who are some of Biocardia's key competitors?

What other stocks do shareholders of Biocardia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocardia investors own include Inseego (INSG), Inpixon (INPX), IGM Biosciences (IGMS), Esperion Therapeutics (ESPR), Editas Medicine (EDIT), Co-Diagnostics (CODX), CNS Pharmaceuticals (CNSP), BioXcel Therapeutics (BTAI), BioNTech (BNTX) and AzurRx BioPharma (AZRX).

Who are Biocardia's key executives?

Biocardia's management team includes the folowing people:
  • Dr. Peter A. Altman, CEO, Pres & Director (Age 52)
  • Mr. David McClung, Chief Financial Officer (Age 56)
  • Mr. Phil Pesta, VP of Operations (Age 53)
  • Dr. Eric Henricus J. Duckers, Chief Medical Officer (Age 51)
  • Dr. Ian McNiece Ph.D., Chief Scientific Officer (Age 65)

When did Biocardia IPO?

(BCDA) raised $51 million in an initial public offering (IPO) on the week of July 20th 2015. The company issued 3,900,000 shares at $12.00-$14.00 per share. Cantor Fitzgerald & Co. acted as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers.

How do I buy shares of Biocardia?

Shares of BCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Biocardia's stock price today?

One share of BCDA stock can currently be purchased for approximately $3.67.

How big of a company is Biocardia?

Biocardia has a market capitalization of $25.05 million. Biocardia employs 27 workers across the globe.View Additional Information About Biocardia.

What is Biocardia's official website?

The official website for Biocardia is http://www.biocardia.com/.

How can I contact Biocardia?

The company can be reached via phone at 650-226-0120.


MarketBeat Community Rating for Biocardia (NYSE BCDA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  12 (Thanks for Voting!)
Underperform Votes:  7 (Thanks for Voting!)
Total Votes:  19
MarketBeat's community ratings are surveys of what our community members think about Biocardia and other stocks. Vote "Outperform" if you believe BCDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/29/2020 by MarketBeat.com Staff

Featured Article: Balance Sheet

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel